Clinical trial / 2003
Green tea demonstrated minimal antitumor activity in androgen-independent metastatic prostate cancer.
In a phase II trial, 42 patients with androgen-independent prostate carcinoma took 6 grams of oral green tea daily in divided doses. Only one patient (2%, 95% CI 1-14%) experienced a tumor response, defined as at least a 50% drop in prostate-specific antigen, and it lasted under two months. Median prostate-specific antigen values increased by 43% by one month. Adverse events occurred in 69% of participants.
- Study type
- Phase II clinical trial
- Who was studied
- 42 asymptomatic men with progressive androgen-independent prostate cancer
- What was measured
- Prostate-specific antigen response and toxicity
THE PAPER
A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.
Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. Cancer, 2003.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.